| P50 | author | Julio Montaner | Q1712378 |
| | Robert S Hogg | Q37837778 |
| | Bohdan Nosyk | Q90801622 |
| | Benita Yip | Q114738779 |
| | STOP HIV/AIDS Study Group | Q117254133 |
| P2093 | author name string | Viviane D Lima | |
| | Jeong Min | |
| P2860 | cites work | Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 |
| | Lack of evidence for changing virulence of HIV-1 in North America. | Q30367604 |
| | Comparison of smoothing techniques for CD4 data in a Markov model with states defined by CD4: an example on the estimation of the HIV incubation time distribution | Q30669400 |
| | Computing short-interval transition matrices of a discrete-time Markov chain from partially observed data | Q31116345 |
| | Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study | Q33989047 |
| | Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. | Q34289633 |
| | The direct costs of HIV/AIDS care | Q34497622 |
| | Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection | Q34740804 |
| | The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States | Q35214966 |
| | Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report | Q36263674 |
| | Antiretroviral therapy in prevention of HIV and TB: update on current research efforts | Q36493044 |
| | Cost-effectiveness of HIV testing and treatment in the United States | Q36628399 |
| | A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection | Q37823555 |
| | The impact of disease stage on direct medical costs of HIV management: a review of the international literature | Q37823559 |
| | Natural history of HIV infection | Q38223417 |
| | A maximum likelihood estimator of a Markov model for disease activity in Crohn's disease and ulcerative colitis for annually aggregated partial observations | Q38449675 |
| | HIV antiretroviral treatment: early versus later. | Q39724677 |
| | Effect of gender, age, transmission category, and antiretroviral therapy on the progression of human immunodeficiency virus infection using multistate Markov models. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine | Q40837195 |
| | Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. | Q41002448 |
| | The validity of inferences based on incomplete observations in disease state models | Q41846283 |
| | Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events | Q42620594 |
| | Multi-state Markov models for disease progression in the presence of informative examination times: an application to hepatitis C. | Q42996783 |
| | Determinants of the cost of health services used by veterans with HIV. | Q43428451 |
| | Modeling markers of disease progression by a hidden Markov process: application to characterizing CD4 cell decline | Q43986083 |
| | Transition probabilities and predictors of adherence in a California Medicaid population using antihypertensive and lipid-lowering medications | Q44175993 |
| | Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy | Q44404808 |
| | Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease | Q46455671 |
| | Markov modelling of immunological and virological states in HIV-1 infected patients | Q46922355 |
| | Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. | Q51108701 |
| | A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy. | Q51701524 |
| | Estimation of the transition matrix of a discrete-time Markov chain. | Q52048605 |
| | Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. | Q53971103 |
| | Epidemiology of Antiretroviral Multiclass Resistance | Q57259606 |
| | Markov modelling of HIV infection evolution in the HAART era | Q61865985 |
| | Effect of CD4+ cell count measurement variability on staging HIV-1 infection | Q67885079 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | anti-retroviral agent | Q50430310 |
| P304 | page(s) | 653-659 | |
| P577 | publication date | 2013-08-01 | |
| P1433 | published in | Journal of Acquired Immune Deficiency Syndromes | Q6294722 |
| P1476 | title | HIV-1 disease progression during highly active antiretroviral therapy: an application using population-level data in British Columbia: 1996-2011. | |
| P478 | volume | 63 | |